About Adenios

About company

Adenios technology both raises and lowers the permeability of the blood brain barrier to precisely control the delivery of existing drugs. The technology, spun out of Cornell University, can be paired with unmodified current therapeutics to either improve or block delivery of multiple compounds into the brain. The technology platform is currently in pre-clinical development aimed at controlling delivery of therapeutics for treatment of Alzheimer's, Parkinson's, brain cancer, multiple sclerosis, and other central nervous system diseases.